Shire says it expects reduced sales growth in 2015 compared with last year as the U.S. dollar continues to strengthen, the hereditary angioedema (HAE) drug Cinryze–acquired with ViroPharma—begins its first full year in Shire’s portfolio, and the ADHD drug Intuniv begins its first full year without patent exclusivity.

For 2015, Shire said it expects “low-to-mid single digit product sales growth” based on actual exchange rates, and mid-to-high single digit growth at constant exchange rates, and even a low double-digit gain when Intuniv sales are excluded.

The biotech giant finished the fourth quarter of 2014 with $2.172 billion in net income, up 64% from a year earlier, on total revenues of $1.576 billion, up nearly 19%. But Shire benefited from the $1.635 billion fee it received after a planned acquisition by AbbVie fell through, as well as sales numbers that grew through acquisitions, such as Shire’s $4.2 billion purchase of ViroPharma.

The ViroPharma deal expanded Shire’s portfolio with drugs that included Cinryze, which generated $503 million in 2014 sales. Cinryze numbers reflect 30% pro forma growth over 2013, but 18% pro forma growth when the time period is extended beyond 2013 into the first three-plus weeks of last year before the ViroPharma deal was completed on January 23, 2014, Shire cautioned.

The increase, Shire said, was primarily driven by more patients using the therapy, and to a lesser extent the impact of a price increase in the U.S. and an increase in inventory.

Cinryze, a prophylactic treatment for HAE, became Shire’s fourth-largest selling drug in 2014. The ADHD treatment Vyvanse retained its position as Shire’s biggest seller last year with $1.449 billion in sales (up 18% from 2013), primarily due to price increases and to a lesser extent higher U.S. prescription demand and growth in outside-U.S. product sales, the company said, adding: “This growth was partially offset by a lower level of stocking in 2014 as compared to 2013.”

Vyvanse sales are posed to rise again in 2015, since on January 30, the FDA approved a new indication for the drug, treatment of adults with moderate to severe binge eating disorder.

Shire’s next-highest seller was the ulcerative colitis treatment Lialda/Mezavant with $633.8 million (up 20%), and the Hunter syndrome treatment Elaprase with $592.8 million (up 9%).

Shire’s fastest-growing drug in 2014 was Firazyr. Sales of the acute HAE attack treatment jumped 55% over 2013, to $364.2 million, due to more patients on the therapy and a U.S. price increase.

During Q4 2014, Vyvanse racked up $383 million in sales, up 16% from the final three months of 2013. Lialda/Mezavant followed with $184.7 million (up 24%). Elaprase generated $143.3 million, down 6%—a drop blamed in part by the timing of large orders from markets that order less frequently, as well as currency fluctuations.

Cinrisze was also Shire’s fourth-highest seller in Q4 with $142.4 million, while Firazyr sales nearly doubled in the quarter, zooming 81% to $101.9 million.

In addition to absorbing ViroPharma, Shire said it enjoyed the benefits of sales and pipeline growth in 2014 via its $260 million-plus acquisition of Lumena Pharmaceuticals, particularly in gastrointestinal (GI) drugs. Shire’s GI portfolio is expected to grow further this year when it completes its planned $5.2 billion acquisition of NPS Pharmaceuticals, announced in January.

Shire said it was on track to complete its NPS Pharma acquisition in the first quarter of this year.

On the down side, Shire saw product sales of Intuniv slide 2% in 2014, to $327.2 million, reflecting lower prescription demand due to generic competition, as well as what Shire termed “significantly” higher sales deductions as a percentage of product sales, and destocking of the product compared to 2013. Yet Shire contained Intuniv’s drop through a price increase earlier last year.

“We expect to deliver further growth in 2015 despite significant foreign currency headwinds, the loss of exclusivity for Intuniv, and the inclusion of Cinryze in our 2014 results,” Shire CEO Flemming Ornskov, M.D., said in a statement. “In 2015, Shire is well-positioned on our journey to become a leading global biotech as we complete our One Shire reorganization with the expected benefits of profitability and efficiency, and advance pivotal regulatory and clinical milestones that will contribute to $10 billion in product sales by 2020.